Comparison of Voxel-Wise Tumor Perfusion Changes Measured with Dynamic Contrast-Enhanced (DCE) MRI and Volumetric DCE CT in Patients with Metastatic Brain Cancer Treated with Radiosurgery

Dynamic contrast-enhanced (DCE)-MRI metrics are evaluated against volumetric DCE-CT quantitative parameters as a standard for tracer-kinetic validation using a common 4-dimensional temporal dynamic analysis platform in tumor perfusion measurements following stereotactic radiosurgery (SRS) for brain metastases. Patients treated with SRS as part of Research Ethics Board-approved clinical trials underwent volumetric DCE-CT and DCE-MRI at baseline, then at 7 and 21 days after SRS. Temporal dynamic analysis was used to create 3-dimensional pharmacokinetic parameter maps for both modalities. Individual vascular input functions were selected for DCE-CT and a population function was used for DCE-MRI. Semiquantitative and pharmacokinetic DCE parameters were assessed using a modified Tofts model within each tumor at every time point for both modalities for characterization of perfusion and capillary permeability, as well as their dependency on precontrast relaxation times (TRs), T 10 , and input function. Direct voxel-to-voxel Pearson analysis showed statistically significant correlations between CT and magnetic resonance which peaked at day 7 for K trans (R = 0.74, P ≤ .0001). The strongest correlation to DCE-CT measurements was found with DCE-MRI analysis using voxel-wise T 10 maps (R = 0.575, P < .001) instead of assigning a fixed T 10 value. Comparison of histogram features showed statistically significant correlations between modalities over all tumors for median K trans (R = 0.42, P = .01), median area under the enhancement curve (iAUC 90 ) (R = 0.55, P < .01), and median iAUC 90 skewness (R = 0.34, P = .03). Statistically significant, strong correlations were found for voxel-wise K trans , iAUC 90 , and v e values between DCE-CT and DCE-MRI. For DCE-MRI, the implementation of voxel-wise T 10 maps plays a key role in ensuring the accuracy of heterogeneous pharmacokinetic maps.